Henatinib is an Orally Active Multikinase Inhibitor with Broad Antitumor Activities
Tumor growth and development involve many complex pathways, such as malignant cell proliferation and angiogenesis. Kinases are the enzymes that control signal transduction in these pathways, including VEGF, PDGFR, c-kit, and so on. They are present in stromal vascular or cell-matrix, and when they are dysfunctional (such as overactivation), they...
Telatinib is an Orally Active Inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit
The importance of angiogenesis in solid tumor growth is well established. Inhibition of the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway is now an approved and generally accepted treatment of lung cancer. Interestingly, bevacizumab, a monoclonal antibody against VEGF-A, is predominantly administered in combination with chemotherapy, whereas the...
Dovitinib is a Multi-Targeted Tyrosine Kinase Inhibitor
Tyrosine kinase is an enzyme that can transfer phosphate groups from ATP to tyrosine residues of specific proteins in cells. Specifically, this covalent post-translational modification is a key component of normal cell communication and homeostasis maintenance. Tyrosine kinase is an important mediator of signal cascade reaction. Besides, it plays...
Dasatinib is an Orally Active Dual Bcr-Abl and Src Family Tyrosine Kinase Inhibitor
Src is an important member of the non-receptor protein tyrosine kinase. Furthermore, Src plays a key role in the regulation of many cells through the extracellular ligand binding to the receptor and the cell adhesion molecule activation in cell cycle-specific stage. Src can affect cell adhesion, motility, proliferation, and...